Important Safety Information

This guide is intended to provide information about the management of certain important identified risks when prescribing Tecentriq for urothelial carcinoma and NSCLC, including immune-mediated pneumonitis, hepatitis, colitis or diarrhea, endocrinopathies, , other immune-mediated adverse reactions involving a major organ, infections and infusion related reactions.

All patients receiving treatment with Tecentriq must be given Patient Brochure and Patient Alert Card by their healthcare professional to educate them about the symptoms of immune-mediated adverse reactions and the need to report them to their treating doctor immediately. Treating doctors should also advise their patients to keep the Patient Alert Card with them at all times and show it to any healthcare professional who may treat them.

To obtain copies of the Patient Brochure and Patient Alert Card, please download or contact Roche Israel via Roche Israel website at http://www.roche.co.il/ 

For more information, please refer to TECENTRIQ® prescribing information. 

Any suspected adverse events should be reported to the Ministry of Health according to the National Regulation by using an online form: https://www.gov.il/he/service/side_effects_reports or by referring to Roche Pharmaceuticals Israel Drug Safety in the following mail: israel.drugsafety@roche.com

MatCode Approval No.: -1905-V2-3253